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Abstract
Background—Hispanic women have lower breast cancer incidence rates than non-Hispanic 
white (NHW) women. To what extent genetic versus non-genetic factors account for this 
difference is unknown.
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Methods—Using logistic regression, we evaluated the interactive influences of established risk 
factors and ethnicity (self-identified and identified by ancestral informative markers) on breast 
cancer risk among 2326 Hispanic and 1854 NHW postmenopausal women from the US and 
Mexico in the Breast Cancer Health Disparities Study.
Results—The inverse association between % Native American(NA) ancestry and breast cancer 
risk was only slightly attenuated after adjusting for known risk factors [lowest versus highest 
quartile: odds ratio(OR)=1.39, 95% confidence interval(CI)=1.00–1.92 among US Hispanics; 
OR=1.92 (1.29–2.86) among Mexican women]. The prevalence of several risk factors, as well as 
the associations with certain factors and breast cancer risk, differed according to genetic 
admixture. For example, higher BMI was associated with reduced risk among women with lower 
NA ancestry only [BMI <25 versus >30: OR=0.65 (0.44–0.98) among US Hispanics; OR=0.53 
(0.29–0.97) among Mexicans]. The average number of risk factors among cases was inversely 
related to % NA ancestry.
Conclusions—The lower NA ancestry groups were more likely to have the established risk 
factors, with the exception of BMI. While the majority of factors were associated with risk in the 
expected directions among all women, BMI had an inverse association among Hispanics with 
lower NA ancestry.
Impact—These data suggest that the established risk factors are less relevant for breast cancer 
development among women with more NA ancestry.
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Introduction
In the United States (US), age-adjusted breast cancer incidence rates are about 25% lower 
among Hispanics/Latinas than among non-Hispanic white (NHW) women (1). This 
difference in breast cancer incidence is likely due to differences in genetic, reproductive, 
hormonal, lifestyle and environmental factors. To what extent genetic versus non-genetic 
factors, independently and interactively, account for this difference has not been well 
defined.
Hispanics are a genetically heterogeneous population (2), representing a mix of primarily 
European and Native American genotypes (3). Genetic admixture studies using ancestral 
informative markers (AIMs) of European and Native American ancestry have indicated that 
higher European ancestry is associated with increased breast cancer risk among both US 
Hispanic and Mexican women (2–5). The consistency of this observation is concordant with 
the discovery of a genetic variant near the estrogen receptor 1 gene (ESR1) that is only 
observed in women with at least some Native American ancestry and is associated with a 
reduced risk of breast cancer (6).
Our previous work within the 4-Corners Breast Cancer Study found several differences in 
the impact of known breast cancer risk factors according to self-reported ethnicity in a US 
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population (7). We estimated that about two-thirds of breast cancers could be attributed to 
known risk factors among NHW women as compared with under one-third among Hispanic 
women (7). We now know that Hispanic women have genetic factors that lower the risk of 
breast cancer development. We hypothesize that there might be ancestry/ethnic-specific 
differences in the way that non-genetic factors affect breast cancer risk.
The diversity in genetic ancestry and lifestyle exposures among Hispanic and NHW women 
provides an opportunity to evaluate the influence of genetic versus non-genetic risk factors, 
thereby contributing to a more complete understanding of breast cancer etiology and 
possible causes for the observed disparities in incidence. We explored the interactive 
influences of breast cancer risk factors and both self-identified ethnicity and genetic ancestry 
estimates (AIMs) on breast cancer risk among postmenopausal women from the US and 
Mexico.
Materials and Methods
Study population
The Breast Cancer Health Disparities Study is comprised of participants from three 
population-based case-control studies: the 4-Corners Breast Cancer Study, the San Francisco 
Bay Area Breast Cancer Study, and the Mexico Breast Cancer Study. These three studies 
have been described in detail elsewhere (8–10). Briefly, participants from the 4-Corners 
Breast Cancer Study were NHW, Hispanic, or Native American women living in non-
reservation areas in the states of Arizona, Colorado, New Mexico, or Utah at the time of 
diagnosis (or selection). Cases were ages 25 to 79 years with a histological confirmed 
diagnosis of in situ or invasive cancer between October 1999 and May 2004; controls were 
selected from the target and frequency matched on ethnicity and 5-year age distribution of 
cases. In Arizona and Colorado, controls under 65 years old were randomly selected from a 
commercial mailing list. In New Mexico and Utah, they were randomly selected from 
driver’s license lists. In all states, women 65 years and older were randomly selected from 
the Center for Medicare Services lists. Participants from the San Francisco Bay Area Breast 
Cancer Study were women ages 35 to 79 years from the San Francisco Bay Area. Cases 
were women diagnosed with a first primary histologically confirmed invasive breast cancer 
between April 1997 and April 2002, and controls were identified through random-digit 
dialing, frequency-matched by ethnicity and age distribution. Participants from the Mexico 
Breast Cancer Study were women ages 28 to 74 years, living in the states of Monterrey or 
Veracruz or in Mexico City. Cases were women diagnosed with either a new histologically 
confirmed in situ or invasive breast cancer between January 2004 and December 2007, 
whereas controls were women randomly selected from the catchment area of the cases using 
a probabilistic multi-stage design.
Prior studies have observed a stronger association between genetic admixture and breast 
cancer risk among postmenopausal versus premenopausal women (4, 5). Given this evidence 
and the limited power to adequately evaluate three-way interactions by menopausal status, 
this analysis was restricted to postmenopausal women who had both genetic and risk factor 
data available. This analysis included 875 NHW cases and 979 NHW controls, 614 US 
Hispanic cases and 785 US Hispanic controls, and 426 Mexican cases and 501 Mexican 
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controls. Due to relatively small number of Native American women (55 cases and 73 
controls) in the 4-Corners Breast Cancer Study, they were included with Hispanic women. 
Ethical approval of this study was obtained by the Institutional Review Boards at the 
University of Colorado, the University of Utah, the University of Arizona, the University of 
New Mexico, the Cancer Prevention Institute of California, the Instituto Nacional de Salud 
Publica (INSP), and the Instituto Mexicano de Seguridad Social (IMSS). All participants 
signed informed written consent prior to participation.
Risk factor data
Data were harmonized across all study centers and questionnaires (5). This process involved 
transforming of variables that used the same or the closest information possible and 
assessing the distribution of variables across studies for comparability. Women who reported 
still having periods during the referent year (defined as the calendar year before diagnosis 
for cases or before selection into the study for controls) without taking menopausal hormone 
therapy (HT) were classified as pre-menopausal. Women were classified as post-menopausal 
if they met any of the following criteria: 1) reported a natural menopause, or 2) were still 
having periods while taking HT and were at or above the 95th percentile of age for those 
who reported having a natural menopause (i.e., ≥12 months since their last period). Age at 
menopause was site and ethnic-specific: 58 years for NHW and 56 for Hispanic women 
from the 4-Corners Breast Cancer Study; 54 for the Mexico Breast Cancer Study; and 55 for 
NHW and 56 for Hispanic women from the San Francisco Bay Area Breast Cancer Study.
The following variables were included in this analysis: age at menopause (<50, ≥50 years), 
HT use (never, former, current use), age at menarche (≤11, 12–13, ≥14 years), family history 
of breast cancer among first-degree relatives (yes, no), parity and age at first full-term live or 
still birth (nulliparous, 1–2 births at age <25 years, 1–2 births at age ≥25 years, ≥3 births at 
age <25 years, ≥3 births at age ≥25 years), breast-feeding (never, ≤12, >12 months), body 
mass index (BMI) (<25, 25–29.9, ≥30 kg/m2), and alcohol intake (none, <10 g/day, ≥10 g/
day). With the exception of BMI, all variables were self-reported. BMI (kg/m2) was 
calculated based on self-reported weight (kg) in the reference year and height (m) measured 
at interview. Self-reported height was utilized for those who were missing measurement 
data. Alcohol intake was based on lifetime average intake (4-Corners and Mexico subjects), 
or intake during the reference year (SFBCS). All multivariable models were also adjusted 
for age (continuous) and study center (4-Corners or San Francisco Bay Area for US-based 
analyses only). A total of 104 AIMs were genotyped in order to provide an estimate of 
European and Native American ancestry (11).
Genetic data
DNA was extracted from either whole blood (7286 subjects) or mouthwash samples (637 
subjects) provided by study participants. Whole Genome Amplification (WGA) was applied 
to the mouthwash derived DNA samples prior to genotyping. Genotyping was conducted as 
part of a larger study of 1,466 single nucleotide polymorphisms (SNPs) in 205 candidate 
genes in several inflammation-related pathways hypothesized to be involved in breast 
carcinogenesis (5). A total of 104 AIMs were included to estimate European and Native 
American ancestry (11). As previously described, genotyping was done using a multiplexed 
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bead array assay format based on GoldenGate chemistry (Illumina, San Diego, California). 
A genotyping call rate of 99.93% was attained (99.65% for WGA samples). For quality 
control, 132 internal replicates were included, representing 1.6% of the sample set. The 
duplicate concordance rate was 99.996% as determined by 193,297 matching genotypes 
among sample pairs.
Statistical analyses
All statistical analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, NC). 
Bivariate analyses were utilized to compare averages (or proportions) of risk factors between 
controls and/or cases within and across the different ethnic or admixture groups. Statistical 
significance was based on two-sided tests at a significance level of less than 0.05. Logistic 
regression models were utilized to compute odds ratios (ORs) and 95% confidence intervals 
(CIs) to evaluate the ethnic-specific relationship between genetic admixture (quartiles) and 
postmenopausal breast cancer risk among women in the US and Mexico, as well as the 
relationships between risk factors and breast cancer risk among postmenopausal women 
according to genetic admixture (below or above the population-specific median values) 
among Hispanic women in the US and Mexico. Data were stratified by ethnic and/or genetic 
admixture groups to obtain ethnic/admixture-specific risk estimates. Ethnic/admixture-
specific risk estimates were also evaluated based on ER status for US subjects only.
Separate analyses were performed for the US and Mexico studies because of the 
considerable differences in the distributions of the genetic and non-genetic risk factors, as 
well as the potential for confounding by unmeasured risk factors (2). The relationship 
between % NA ancestry and postmenopausal breast cancer risk was evaluated using 
quartiles within each ethnic/regional group. Among ordinal variables, a Wald P value for 
linear trend was obtained when converting the variable from categorical to numerical data 
and including it in the multivariable regression model. For all risk factors, a P value for 
interaction was obtained from the Wald P value when creating an interaction term between 
each risk factor and the ethnic/admixture group within each region.
Comparative density plots based on the distribution of total number of aforementioned risk 
factors among cases and controls were created using SAS. Two sample t-tests and one-way 
ANOVAs (Bonferroni correction for pairwise comparisons) were used to obtain P values for 
comparisons with the average number of risk factors across the ethnic/admixture groups.
Results
Among US controls, NHWs were significantly more likely to have many of the established 
risk factors compared to Hispanics (P < 0.05) (Table 1). The only risk factor that US 
Hispanics were more likely to report was a higher BMI. Interestingly, this pattern was 
similar when comparing US Hispanics to Mexican controls. US Hispanics were significantly 
more likely to have all of the same risk factors when compared to Mexican women, whereas 
Mexican women had a higher BMI. As expected, there were large differences in the % NA 
ancestry, with NHW controls having the lowest (4%), followed by US Hispanics (41%) and 
Mexicans (71%). Among US cases, Hispanic women had a higher percentage of ER 
negative tumors compared with NHW women (23.3% versus 18.1%).
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Overall, a wide range of % NA ancestry was observed among Hispanic women (IQR = 32 to 
54 % for US; IQR = 56 to 84% for Mexico). Despite considerable differences in the 
distribution of % NA ancestry between US Hispanic and Mexican women, having less NA 
ancestry was associated with higher breast cancer risk in both populations (Table 2). This 
association was only slightly diminished after adjusting for known risk factors, and 
remained statistically significant or marginally significant (bottom versus top quartile: OR = 
1.39; 95% CI = 1.00 to 1.92, Ptrend = 0.04 among US Hispanic women; OR = 1.92; 95% CI 
= 1.29 to 2.86, Ptrend = 0.004 among Mexican women). When stratified by ER status, the 
association appeared to be stronger among ER negative cases (Supplemental Table 1). 
However, the percentage of ER positive tumors did not differ based on quartile of % NA 
ancestry within ethnic group. No association with NA ancestry was observed among NHW 
women, who had a very limited range of % NA ancestry (interquartile range (IQR) = 1.8 to 
4.7%), irrespective of ER status (Table 2 and Supplemental Tables 1 and 2).
To explore the influence of NA ancestry on the relationship between the described risk 
factors and postmenopausal breast cancer risk, the population was stratified according to 
region, self-reported ethnicity and % NA ancestry (below or above the median) (Table 3). 
Among NHW women, the majority of factors evaluated were associated with breast cancer 
risk in the expected direction. Specifically, positive family history, younger age at menarche, 
and older age at menopause were significantly associated with increased risk. Associations 
with low parity/older age at first birth, alcohol consumption and no prior history of breast-
feeding were also in the expected direction, although they were weak and not statistically 
significant.
Among Hispanic women with lower % NA ancestry, factors significantly associated in the 
expected direction included positive family history and current HT use. Associations with 
age at menarche, breast-feeding, and parity/age at first birth were in the expected direction, 
though not statistically significant. In contrast, BMI was significantly inversely associated 
with risk. Among US Hispanic women with higher % NA ancestry, positive family history, 
later age at menopause, and current HT use were significantly associated with increased 
breast cancer risk. No history of breast-feeding was associated with a marginally significant 
increased risk. When comparing across all US cases, BMI was the only risk factor that was 
associated in the unexpected direction among Hispanic women with lower % NA ancestry 
only. Higher BMI was associated with reduced breast cancer risk among US Hispanic 
women with lower NA ancestry only (BMI <25 versus > 30 kg/m2: OR = 0.65, 95% CI = 
0.44 to 0.98), although there was no statistically significant interaction when comparing 
these groups (Table 3).
Among Mexican women with lower % NA ancestry (Table 4), positive family history, low 
parity/older age at first birth, HT use, alcohol consumption and no history of breast-feeding 
(borderline, P = 0.06) were associated with increased breast cancer risk. A non-significant 
positive association was observed with younger age at menarche. Among Mexican women 
with higher % NA ancestry, most associations were in the expected direction, but only 
family history was significant (wide CIs). Non-significant elevated ORs were found for low 
parity/older age at first birth, younger age at menarche and alcohol consumption. The only 
risk factor with an unexpected association was BMI. Similar to the US Hispanics, higher 
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BMI was associated with reduced breast cancer risk among women with lower NA ancestry 
only (BMI <25 versus > 30kg/m2: OR=0.53; 95% CI = 0.29 to 0.97) among Mexican 
women), although this interaction was not statistically significant. There was a suggestive 
interaction for no history of breastfeeding (Pinteraction = 0.06), but only among Mexican 
women with lower % NA ancestry.
When stratified by ER status, there were no notable differences in any of the observed 
relationships (Supplemental Tables 3 and 4). However, power was limited, and data were not 
available for Mexican cases. The inverse relationship between BMI and breast cancer risk 
observed among US Hispanic women with lower NA ancestry appeared to be more relevant 
for risk of ER negative breast cancer (BMI <25 versus BMI > 30: OR=0.30; 95% CI = 0.14 
to 0.65 for ER negative BC; OR=0.86; 95% CI = 0.52 to 1.43 for ER positive BC); however, 
there was limited power to assess these relationships by tumor subtype.
Among US postmenopausal cases, the prevalence of risk factors was highest among NHWs, 
intermediate among Hispanics with lower % NA ancestry, and lowest among Hispanics with 
higher % NA ancestry (Table 5). There were a few exceptions: 1) history of breast-feeding 
was comparable across the groups, 2) Hispanics with lower % NA had a younger age at 
menarche, and 3) Hispanics were more likely to be overweight. When comparing Hispanic 
cases from the US and Mexico, the prevalence of many of the risk factors was much lower 
for Mexican cases, including positive family history, no history of breast-feeding, HT use 
and alcohol consumption. Similarly, Mexican cases were more likely to have a higher BMI 
compared with US Hispanic women.
When comparing the direction of the association with risk factors (Table 5), family history 
was the only risk factor that was significantly associated with breast cancer risk among all 
subgroups. In general, associations with low parity/older age at first birth were in the 
expected direction across all subgroups, although weak and not significant for some 
subgroups. With the exception of BMI, all other risk factors were associated in the expected 
direction among at least two of the subgroups. There were no obvious patterns or trends with 
respect to associations with risk factors when comparing regional, ethnic and genetic 
admixture groups. Overall, differences in the prevalence of risk factors were more 
pronounced than differences in the magnitude of associations when comparing ORs across 
the different groups.
We hypothesized that women with breast cancer, on average, should have a higher number 
of risk factors when compared to controls, irrespective of region, ethnicity or extent of NA 
ancestry. Furthermore, if these factors behaved similarly across ethnic populations such that 
the observed increase in incidence rate among Hispanics who immigrate to the US is solely 
due to acquiring more risk factors, then we would expect to see US Hispanic cases 
possessing a relatively similar number of risk factors as NHW cases. To explore this, we 
compared the distribution of the total number risk factors that cases and controls had 
according to region, ethnicity and % NA group (Figure 1). Cases were more likely to have a 
higher average number of the evaluated risk factors compared to controls for all subgroups 
(4.24 versus 3.91, P < 0.0001 for NHW; 3.88 versus 3.60, P = 0.02 for US Hispanic, low 
NA; 3.64 versus 3.20, P = 0.0002 for US Hispanic, high NA; 3.07 versus 2.24, P < 0.0001 
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for Mexico, low NA; 2.66 versus 2.34, P = 0.01 for Mexico, high NA). Additionally, the 
average number of risk factors differed according to ethnicity and region (data not shown), 
with NHW cases having the highest, followed by US Hispanics, and Mexican cases (P < 
0.05). Differences were also observed according to admixture group within a region (P = 
0.056 when comparing low and high admixture groups among US Hispanic cases and P = 
0.005 among Mexican cases).
Discussion
As previously reported (2–5), higher NA ancestry is associated with lower risk of 
postmenopausal breast cancer among Hispanic women residing in either the US or Mexico. 
The risk estimates were only slightly attenuated when adjusting for known breast cancer risk 
factors. When evaluating the relationship between these risk factors and postmenopausal 
breast cancer risk according to level of NA ancestry, we observed considerable differences in 
risk factor prevalence. Overall, risk factor prevalence and extent of NA ancestry were 
inversely related: the proportion of women with a given risk factor was highest among NHW 
women, intermediate among US Hispanics, and lowest among women living in Mexico. 
Likewise, within each region, the lower NA ancestry groups were more likely to have risk 
factors than those with higher NA ancestry. BMI was the one exception where women with 
more NA ancestry were more likely to have a higher BMI.
There were no striking differences or trends when comparing the magnitude and direction of 
the associations between reported risk factors and breast cancer among regional and ethnic 
subgroups. The majority of factors we evaluated were associated with risk in the expected 
directions among women in each group, although not all reached statistical significance. 
Overall, the majority of the associations did not appear to be dependent upon ER status. 
However, we did not have data on ER status for Mexico, and we had limited power among 
US Hispanics. A suggestive inverse association was observed with BMI and breast cancer 
risk among US Hispanic and Mexican women with lower NA ancestry. An inverse 
relationship between BMI and risk of ER negative breast cancer has been observed among 
postmenopausal African-American women (12). Interestingly, our data also supported a 
stronger inverse relationship for risk of ER negative breast cancer. This could be partially 
attributed to Hispanic women with lower % NA having more African influence, since 
Hispanic populations have been shown to have between 0–8% African ancestry. However, 
these results should be interpreted cautiously due to small sample size. Since the intent of 
this analysis is to assess risk factors collectively, our interpretations of this finding are 
speculative. A more in-depth analysis with BMI on this study population has been conducted 
(13, 14). We did not have sufficient power in this analysis to evaluate BMI according to 
hormone therapy use, which has been shown to mask the effect of BMI.
In the US, Hispanic women have a higher prevalence of obesity compared to NHW women, 
yet lower rates of postmenopausal breast cancer (1, 15). The few studies that have evaluated 
the relationship between obesity and breast cancer among Hispanic women are conflicting 
(16–21). BMI is a large determinant of endogenous sex steroid hormone levels among 
postmenopausal women, a speculated mechanism for the associated increase in breast cancer 
risk (22). Independent of ethnic differences in BMI, some studies have found differences 
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between Hispanics and NHWs with respect to endogenous steroid hormone levels, while 
others have not (23, 24). Obesity and body size may also affect risk through other 
mechanisms, such as influencing inflammatory and insulin-related pathways (25–27). It is 
unknown whether the hypothesized biological mechanisms behave similarly among the 
different populations, and additional research is warranted.
Breast cancer risk is higher in US-born Hispanics than foreign-born, and risk increases with 
longer duration of residency, which is at least partially attributed to changes in risk factor 
profiles from acculturation (9, 28). Our previous work found that known risk factors account 
for fewer breast cancers among Hispanic women, suggesting that there are other unidentified 
factors involved (7). The findings from this study provide additional evidence for the 
contribution of both known and yet to be identified risk factors among Hispanic women. We 
do observe an increase in the prevalence of many risk factors among US Hispanics when 
compared with Mexican women, and the average total number of risk factors among cases is 
significantly higher than among controls, irrespective of region, ethnicity and NA ancestry. 
However, the average number of risk factors among breast cancer cases is inversely related 
to extent of NA ancestry, suggesting that breast cancer development among Hispanic women 
is not just the consequence of acquiring more risk factors such that their profile simply 
resembles that of NHW women. Additionally, a shift in risk factor profile cannot explain the 
observed ethnic differences in tumor characteristics. For example, US Hispanic women are 
more likely to have tumor characteristics associated with poorer prognosis, such as estrogen 
receptor-negative tumors, and these differences are not solely attributed to socioeconomic 
factors (29–31). These data suggest that certain genetic and/or non-genetic factors that 
contribute to breast cancer among Hispanic women differ from those among NHW women.
Irrespective of ethnicity, region or extent of NA ancestry, having a positive family history 
was associated with an increase in breast cancer risk. Interestingly, the proportion of women 
with a family history declined with increasing % NA ancestry, reflecting both the differences 
in overall breast cancer incidence and possible genetic differences in breast cancer 
susceptibility. Given that this is a case-control study, there is also the potential for culturally 
driven recall differences that may contribute to the observed differences in ancestry. Little is 
known about the effects of genetic and/or non-genetic factors within the context of genetic 
background on breast cancer risk. We previously found that some of the associations with 
SNPs identified by previous GWAS exploration were stronger among women with 
intermediate to high levels of NA ancestry and similar between the Hispanic women with 
low NA ancestry and NHWs (32). In addition, a GWAS conducted in a sample of Hispanic/
Latina women reported the finding of a protective variant of Native American origin (6). In 
future studies it would be important to combine information on non-genetic risk factors with 
information on genetic risk factors to evaluate what proportion of the genetic ancestry-breast 
cancer risk association can be explained by these known factors.
This study has both strengths and weaknesses. This study represents one of the largest 
comparative breast cancer studies among Hispanic and NHW women. The availability of 
genetic admixture data provides the unique opportunity to explore gene-environment 
interactions and provides insight into ethnic differences in breast cancer risk. Our study did 
not include estimates of African ancestry, a minor component representing between 0–8% of 
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the ancestral background of Hispanic women from Mexico and Central America. However, 
when we compared the Indigenous American ancestry estimates obtained with a two-way 
admixture model to those obtained with a supervised three-way admixture model in a subset 
of these Hispanic women, the use of a two-way admixture model was shown to be adequate 
(2). In spite of our large sample size, power was limited to assess differences in risk 
according to tumor characteristics partly due to the lack of this information for the Mexico 
cases.
This study was prompted by the accumulating evidence suggesting that either genetic and/or 
non-genetic factors may modify susceptibility to the development of breast cancer among 
Hispanic women. As previously shown, NA ancestry is associated with lower breast cancer 
risk even after accounting for differences in established breast cancer risk factors. In 
addition, our data suggest that these breast cancer risk factors, as a whole, contribute less to 
breast cancer development among women with more NA ancestry, and further research is 
needed to gain a better understanding of how genetic and non-genetic risk factors act 
independently and collectively to affect risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The average number of risk factors among breast cancer cases is inversely related to 
extent of Native American (NA) ancestry
Breast cancer cases were more likely to have a higher average number of the evaluated 
breast cancer risk factors compared to controls, irrespective of region, self-reported ethnicity 
and % NA ancestry. These comparative density plots were based on the distribution of total 
number of risk factors among cases and controls, as categorized in Table 5.
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